Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on in-pentetreotide spect imaging

Nuclear Medicine Communications

Volumn 25, Issue 3, 2004, Pages 253-257

  Gopinath, Gnanasegaran ^a   Ahmed, Akhtar ^a   Buscombe, John R ^a   Dickson, John C ^a   Caplin, Martyn E ^a   Hilson, Andrew J W ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

In pentetreotide; SPECT tumour volume response

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PENTETREOTIDE IN 111; POLYVINYL ACETATE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN Y 90; STREPTOZOCIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; CALCULATION; CARCINOID; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; FLUSHING; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; NEUROENDOCRINE TUMOR; PAIN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANATOMY, CROSS-SECTIONAL; CARCINOID TUMOR; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 1642366080     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200403000-00007     Document Type: Article

References (13)

1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352:799-805.
2. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, et al. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and fluorouracil. Clin Endocrinol 2002; 57:169-183.
3. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 15 (86):944-948.
4. DeJong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32:133-140.
5. Schell SR, Camp ER, Caridi JG, Hawkins IF Jr. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 2002; 6:664-670.
6. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002; 38:1817-1823.
7. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, et al. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion 1994; 55 (Suppl 3):54-59.
8. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 2001; 37:1-3.
9. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001; 74:983-986.
10. Kimura M, Tominga T. Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer. Breast Cancer 2002; 9:153-159.
11. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62 (Suppl 1):73-78.
12. Sakamoto H, Nakai Y, Ohashi Y, Matsuda M, Sakashita T, Nasako Y, et al. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas. Acta Otolaryngol Suppl 1998; 538:254-260.
13. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, et al. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors. J Clin Oncol 1998; 16:2534-2541.